Skip to main content

Dr Reddy's Laboratories Ltd

Stage 4 · Declining · week 9

As of 9 Oct 2026, Dr Reddy's Laboratories is in Stage 4 — declining, a downtrend, in week 9 (since 6 Aug 2026). It closed at ₹1,197, 13.0% below its 52-week high and below its 200-day average, which is falling. In Health Care, 44.6% of stocks are in Stage 2.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. More about the company

₹1,197
+1.44% today
₹99,709 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

Declining — below its long-term trend

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is DRREDDY early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
vs 52W High
-13.0%
₹1,135.6 lo₹1,375.7 hi
13.0% below 52W high — failed near resistance
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 9
1w13w26w
Week 9 — established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-3.9%
200 DMA: ₹1,245.2 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.85x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↗ ⇈
Accelerating · MA20 +2.2% vs MA50 -1.5% / 10d
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+4.0%
3M
-3.8%
6M
+0.5%
YTD
-6.7%
1Y
-3.8%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
Sector has 74 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 58 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-14 → 2026-10-09
S2 15w
S2 22w
S2 14w
S2 16w
2023-07-142026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 15w → S3 6w → S2 22w → S3 8w → S2 14w → S3 8w → S4 4w → S1 1w → S2 2w → S1 2w → S2 1w → S1 1w → S4 13w → S1 5w → S2 8w → S3 6w → S2 6w → S3 9w → S4 6w → S1 3w → S2 16w → S3 1w → S4 9w current
Total tracked: 166 weeks across 23 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-04-01
6 appearances in last 60 days. First seen: 2024-07-08.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S4
Wk 9 · Vol 0.85x
2026-10-08S4
Wk 9 · Vol 1.28x
2026-10-07S4
Wk 9 · Vol 1.00x
2026-10-06S4
Wk 9 · Vol 0.90x
2026-10-05S4
Wk 9 · Vol 1.62x
2026-10-01S4
Wk 8 · Vol 1.38x
2026-09-30S4
Wk 8 · Vol 2.17x
2026-09-29S4
Wk 8 · Vol 2.98x
2026-09-28S4
Wk 8 · Vol 1.92x
2026-09-25S4
Wk 8 · Vol 0.56x
2026-09-24S4
Wk 7 · Vol 0.93x
2026-09-23S4
Wk 7 · Vol 0.55x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹1,181.2
200 DMA
₹1,245.2
52W High
₹1,375.7
52W Low
₹1,135.6
5D Low
₹1,180
Resistance levels (recent highs)
20d High
₹1,251.9
60d High
₹1,251.9
120d High
₹1,375.7
250d High
₹1,375.7
Next resistance
+4.6%
to 20d High
P/E (TTM)
26.2
Forward 20.4
Earnings Growth (YoY)
-86.2%
Revenue -11.6%
ROE
+11.8%
Profit margin +12.8%
Dividend Yield
0.60%
P/B 2.9
About this companyHealth Care· Pharmaceuticals

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.